

ASX ANNOUNCEMENT
10 February 2022



NOTICE OF RELEASE FROM ESCROW

NOTICE PURSUANT TO ASX LISTING RULE 3.10A

In accordance with ASX Listing Rule 3.10A, Little Green Pharma Ltd advises that the following securities are due to be released from ASX imposed escrow on 20 February 2022:

Security	Number of securities
Fully paid ordinary shares	55,534,703
Class C performance rights	1,000,000
Class D performance rights	1,000,000
Class E performance rights	1,000,000
Unlisted options – expiring 28-Feb-2022	3,500,000
Unlisted options – expiring 31-July-2022	2,036,768
Unlisted options – expiring 31-July-2022	2,036,768

ENDS

BY ORDER OF THE BOARD

A handwritten signature in black ink, appearing to read 'Alistair Warren', positioned above a horizontal line.

Alistair Warren
Company Secretary

For further information please contact:

Alistair Warren, Company Secretary
Little Green Pharma
E: a.warren@lgp.global
T: +61 8 6280 0050

Fleta Solomon, Managing Director
Little Green Pharma
E: f.solomon@lgp.global
T: +61 8 6280 0050





About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500m² cultivation and 4,000m² GMP manufacturing facility capable of producing over 20 tonnes of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility located in Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass per annum.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp